| Title |
Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, March 2004
|
| DOI | 10.1007/s00280-004-0767-4 |
| Pubmed ID | |
| Authors |
Kin-Tak Chan, Maria Li Lung |
| Abstract |
Chemoresistance is a major problem in the treatment of hepatocellular carcinoma. Certain p53 mutants may enhance drug resistance in cancer cells. To determine whether two frequently occurring p53 mutants, R248Q and R273C, would increase the drug resistance of liver cancer cells, stable cell lines expressing these specific p53 mutants were established by transfecting the p53-null Hep3B cells with mutant p53 expression vectors, and then treating them with the anticancer drugs doxorubicin and paclitaxel. The cells expressing the p53 mutant, R248Q, but not R273C, displayed cross-resistance to both drugs, in contrast to the control cells expressing the vector alone. Moreover, both the expression and the activity of the multiple drug resistance gene product, P-glycoprotein, were elevated in p53 mutant R248Q-expressing cells. Reduced uptake of doxorubicin was also observed in the R248Q-expressing cells. These results suggest that expression of the p53 mutant, R248Q, in liver cancer cells may enhance their drug resistance and that upregulation of P-glycoprotein activity may contribute to this protective effect. |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 27% |
| Student > Bachelor | 6 | 16% |
| Researcher | 5 | 14% |
| Student > Doctoral Student | 3 | 8% |
| Professor > Associate Professor | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 9 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 8 | 22% |
| Biochemistry, Genetics and Molecular Biology | 7 | 19% |
| Medicine and Dentistry | 7 | 19% |
| Immunology and Microbiology | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 10 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2018.
All research outputs
#8,534,528
of 25,373,627 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#728
of 2,562 outputs
Outputs of similar age
#22,450
of 63,329 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#1
of 11 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,562 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 63,329 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.